This HTML5 document contains 193 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://dx.doi.org/10.1002/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q37502039
rdf:type
wikibase:Item
schema:description
wissenschaftlicher Artikel 2011年学术文章 2011年の論文 videnskabelig artikel (udgivet 2011) 2011년 논문 artikulong pang-agham vetenskaplig artikel мақолаи илмӣ artículu científicu espublizáu en 2011 naučni članak 2011年學術文章 articol științific artículo científico publicado en 2011 επιστημονικό άρθρο teaduslik artikkel bilimsel makale научни чланак מאמר מדעי научна статия 2011年学术文章 мақолаи илмӣ artigo científico գիտական հոդված vitskapeleg artikkel scientific article published on 25 July 2011 2011年學術文章 article científic artigo científico (publicado na 2011) artigo científico (publicado na 2011) наукова стаття, опублікована в липні 2011 vědecký článek 2011年学术文章 2011年學術文章 vitenskapelig artikkel mokslinis straipsnis article scientifique publié en 2011 2011 nî lūn-bûn scienca artikolo سائنسی مضمون vedecký článok научни чланак 2011年学术文章 artikull shkencor 2011年學術文章 article scientific tieteellinen artikkeli научная статья ২০১১-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2011ജൂലൈ 25 നു പ്രസിദ്ധീകരിച്ച ശാസ്ത്ര ലേഖനം 2011年学术文章 2011年學術文章 مقالهٔ علمی tudományos cikk articolo scientifico სამეცნიერო სტატია บทความทางวิทยาศาสตร์ bài báo khoa học wetenschappelijk artikel 2011年學術文章 artykuł naukowy مقالة علمية نشرت في 25 يوليو 2011
p:P577
wds:Q37502039-FA91143F-4AFB-489C-B918-6C5B0812DE43
wdt:P577
2011-07-25T00:00:00Z
p:P407
wds:Q37502039-802A60B3-5DD2-4D50-B280-366ECBF61401
wdt:P407
wd:Q1860
p:P2860
wds:Q37502039-B53A2348-53B7-4F43-A391-D78BDA4AFBB9 wds:Q37502039-BF570B19-5DF4-4781-BCAF-B8B6687A00FA wds:Q37502039-8869D324-954F-40F6-B316-5AD09B434BEB wds:Q37502039-88B98CBA-A8CA-458B-81F3-E85C2E193C92 wds:Q37502039-8A624647-D443-49A9-ACC0-FBA7DA9D9D98 wds:Q37502039-991CBC6D-7210-4FC9-B8E2-32F9F24A3B43 wds:Q37502039-CAEFF0E3-4039-4EE5-A41D-428738F766F4 wds:Q37502039-D25333A0-8319-4EFD-B478-ADCAF4F17C32 wds:Q37502039-DD63BFB1-1651-45FB-9604-AC9D9280CEC4 wds:Q37502039-DF00413D-74A2-476C-8183-1EFE6DC2AE58 wds:Q37502039-BFDC1897-8C66-4B09-BB6E-1008BDF99226 wds:Q37502039-C1B4B71B-05F3-4840-A8E0-4165572442E5 wds:Q37502039-67691C18-D2C2-4FEF-B95E-51FE9A226C6E wds:Q37502039-67983323-E7FA-4C6C-9E48-D1430B46FC3A wds:Q37502039-68ABB345-03E2-46AC-8391-C69EE74D69A1 wds:Q37502039-5178F155-3806-49B4-9DA9-5203954F7CCC wds:Q37502039-54901F80-E7E2-4154-B5ED-A69A7C694C76 wds:Q37502039-627A070C-90F9-409A-803A-AEC2D6943407 wds:Q37502039-714E9A9F-B1B8-4D4B-95B2-A8B0DEEC71B5 wds:Q37502039-73C5B68E-3937-4B12-BC35-501FB2744FA6 wds:Q37502039-F87B5E25-1A42-48C4-91D6-0D9518CE37A5 wds:Q37502039-E4F6E334-47C2-43C5-8AF3-6BCFE0B65FFC wds:Q37502039-202033B6-EE7F-418A-87E2-68822CD0FBEC wds:Q37502039-1900C197-8732-4A03-9420-E2B9B02B9E4F wds:Q37502039-1DE37DBE-6575-4620-BC8C-CBC1035B8A22 wds:Q37502039-4B5AC905-2947-4A30-80C1-DD451C31B9E7 wds:Q37502039-4FC6118A-E945-4211-9218-BCAFA1DDD08D wds:Q37502039-506DA2DB-8606-47A0-9F07-A83DC0B72587 wds:Q37502039-47FBF1C0-8EBE-4579-96CC-549A8A9C29A6 wds:Q37502039-10238006-A7D8-4C53-AC1F-3CC56DD2937C wds:Q37502039-126FF51A-1087-48D0-AB7E-31F3DE1186AF wds:Q37502039-16CF670E-A0FA-4331-9C76-ED88FAAE01D7 wds:Q37502039-0A8340CF-6B7B-429C-A07D-0663740272B7
wdt:P2860
wd:Q36025413 wd:Q34613941 wd:Q40164471 wd:Q34005966 wd:Q46931863 wd:Q33566395 wd:Q46336471 wd:Q34460378 wd:Q46616183 wd:Q29616123 wd:Q29616218 wd:Q73865028 wd:Q46972241 wd:Q33767866 wd:Q52533039 wd:Q33575740 wd:Q24648828 wd:Q44918129 wd:Q28300097 wd:Q33379934 wd:Q67921779 wd:Q40289729 wd:Q40590762 wd:Q45198729 wd:Q52222276 wd:Q41304383 wd:Q37287442 wd:Q44558810 wd:Q35074843 wd:Q39850321 wd:Q28513236 wd:Q32040849 wd:Q35607627
p:P2093
wds:Q37502039-EA95BF10-46E6-4858-8D09-18E967B6C299 wds:Q37502039-E75BCABF-1898-40B5-816F-FEBC0C60A686 wds:Q37502039-50AA31E1-D356-4F17-8A9D-2E5D703185CE wds:Q37502039-73E2C036-8959-4D7A-B250-E424C464D2EB wds:Q37502039-86EB7A5D-9033-4B3D-AC0F-EF34318D9D65 wds:Q37502039-A185E6FD-8BFB-4D45-86A3-CC287C3C64B4 wds:Q37502039-140F7332-DA6D-4D1A-BC82-22A625F6A9F8 wds:Q37502039-1858E7C1-31B2-42D3-A299-A93FB37EDD47 wds:Q37502039-25E82B95-6E04-4C5E-8520-D71A65AEE4FA wds:Q37502039-2CF6B4F3-CB37-4B95-9914-421F6A690030 wds:Q37502039-48C5B96C-BA99-4CB6-A1BE-D6547939B48C
wdt:P2093
Gary E Gallick Prashni Paliwal Géralyn C Trudel Mathew Lonberg Edwin Posadas Paul Mathew Christopher J Logothetis Shruti Agrawal Edward L Braud John C Araujo Andrew J Armstrong
rdfs:label
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study
skos:prefLabel
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study
schema:name
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study
p:P1476
wds:Q37502039-F00591BA-19FC-4F2A-AFAB-9FADC6D5547B
wdt:P1476
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study
p:P304
wds:Q37502039-1CADECB5-9045-48AA-AABE-131C7EC74D41
wdt:P304
63-71
p:P31
wds:Q37502039-2A52AF5D-ECDB-446B-AC37-74DF042F47B8
wdt:P31
wd:Q13442814
p:P921
wds:Q37502039-BF924B5B-5225-4598-A7EE-82CF0957C47F wds:Q37502039-7D80D4B6-3786-4883-8780-C3A831EA25E3 wds:Q37502039-24C129CA-651F-42BC-8532-2F2922C4C025 wds:Q37502039-00157A1A-6668-429D-BA6D-C893900B0062
wdt:P921
wd:Q420436 wd:Q419940 wd:Q181257 wd:Q27139135
p:P698
wds:Q37502039-C2F894CC-D388-40E7-9FB0-6F9A9C152471
wdtn:P698
n12:21976132
wdt:P698
21976132
p:P1433
wds:Q37502039-9BE7F8B9-19A2-4909-AA1A-051B4BBFA3AF
wdt:P1433
wd:Q326041
p:P433
wds:Q37502039-26A05821-01CE-444A-9941-B76EA9B9B1ED
p:P478
wds:Q37502039-2AAE8667-7883-4668-AACB-B3813BB90A5B
wdt:P433
1
wdt:P478
118
p:P356
wds:Q37502039-74088618-76A9-4D9D-8C7C-886B42C954D5
wdtn:P356
n8:CNCR.26204
wdt:P356
10.1002/CNCR.26204
p:P5875
wds:Q37502039-69392B53-0637-4A50-A97A-E2DC5AA1686C
wdt:P5875
51696201
p:P932
wds:Q37502039-87389B0A-5F73-4286-A380-A8DF9A4FA7C5
wdt:P932
3898168